FDA warned Biorica International that its Plaquex Oral Dietary Supplement is an unapproved new drug because website claims promote disease treatment and prevention.
What happened
In May 2023, FDA reviewed four websites (plaquex.com, biorica.biz/en, and two Facebook pages) and found they take orders for Plaquex Oral Dietary Supplement. FDA cited claims that the product lowers cholesterol and triglycerides, improves liver and kidney function, prevents plaque, and may prevent heart attack, stroke, amputations, or cancer. FDA determined these claims make it a drug, and because it is not generally recognized as safe and effective for these uses and lacks FDA approval, it is an unapproved new drug and misbranded.
What FDA found
Website claims say Plaquex Oral is intended to treat or prevent diseases, which makes it a drug under the law.
section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]FDA calls it a new drug because it is not generally recognized as safe and effective for the promoted uses and has no FDA approval.
section 201(p) of the Act [21 U.S.C. 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]FDA calls it misbranded because it lacks adequate directions for a layperson to use it safely for its intended diseases.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Selling this misbranded drug in interstate commerce violates the Act.
section 301(a) of the Act [21 U.S.C. 331(a)]
What FDA wants
FDA asks the company to notify it in writing within 15 working days of the specific steps taken to address the violations, with an explanation and supporting documents. If corrective actions cannot be completed in that time, the company must state why and when it will finish; responses go to CFSANResponse@fda.hhs.gov with “CMS 659194” in the subject line.
Who should pay attention
- dietary supplement brands that make disease-treatment claims online
- retailers and distributors selling Plaquex or similar phosphatidylcholine supplements
- quality and regulatory teams reviewing website and social media promotions
This is a summary. Read the original letter on fda.gov.